Current Report Filing (8-k)
May 01 2015 - 8:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date
of earliest event reported): May 1, 2015
LION BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in
Charter)
NEVADA
(State of Incorporation)
000-53127 |
|
75-3254381 |
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
21900 Burbank Boulevard |
|
|
Third Floor |
|
|
Woodland Hills, California |
|
91367 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
|
|
(818) 992-3126
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
| Item 2.02 | Results of Operation and Financial Condition |
Lion Biotechnologies (“we,”
“us,” “our” or the “company”) is currently in the process of finalizing its financial results
for the fiscal quarter ended March 31, 2015. While complete financial information is not available, based on information currently
available, we estimate that as of March 31, 2015, we had approximately $111.3 million of cash and cash equivalents. These preliminary
estimates have been prepared by, and are the responsibility of, our management. Our actual cash and cash equivalents as of March
31, 2015 may differ from these estimates due to the completion of our closing procedures with respect to the fiscal quarter ended
March 31, 2015, final adjustments and other developments that may arise between now and the time the financial results are finalized.
In March 2015, we announced that researchers
from Moffitt Cancer Center reported positive results from a pilot trial of tumor infiltrating lymphocytes (“TIL”) and
ipilimumab in patients with metastatic melanoma. The Phase 1 trial was conducted at the Moffitt Cancer Center in patients with
metastatic melanoma, with the objective of determining the safety and feasibility of combining TIL therapy with the CTLA-4 checkpoint
inhibitor, ipilimumab. The pilot trial was partially sponsored by us. Twelve patients were treated with ipilimumab one week prior
to tumor harvest for TIL expansion, a second time while their TIL were being expanded, and two more times following TIL transfer.
Of the 12 patients enrolled in the trial, 11 went on to receive their autologous TIL, with five out of the 11 TIL-treated patients
(46%) responding to treatment (one complete response and four partial responses), consistent with response rates from previous
TIL studies in metastatic melanoma. Of the 12 enrolled patients, only one (8%) was ineligible for TIL transfer, indicating relatively
high patient adherence to trial protocol.
This Current Report on Form 8-K contains
forward-looking statements, including statements regarding expected financial results as of March 31, 2014. These forward-looking
statements are based on management’s beliefs and assumptions and on information currently available to management. Management
believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on
any such forward-looking statements because such statements speak only as of the date when made. The company does not undertake
any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties
that could cause actual results, events and developments to differ materially from the Company’s historical experience and
its present expectations or projections. These risks and uncertainties include, but are not limited to, risks related to changes
in estimated financial amounts based on the completion of financial closing procedures and the audit of the financial statements
and market risks and uncertainties, as well as those described in “Item 1A. Risk Factors” and elsewhere in the Company’s
Annual Report on Form 10-K and those described from time to time in other reports which the Company files with the Securities and
Exchange Commission.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
LION BIOTECHNOLOGIES, INC. |
|
|
|
Date: May 1, 2015 |
By: |
/s/MICHAEL HANDELMAN |
|
|
Michael Handelman, Chief Financial Officer |
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024